UK scientists have developed a new drug to treat Covid-19.

Developed by UK bio-tech company Synairgen, it uses a protein called interferon beta, which our bodies produce when we get a viral infection.

Initial results from the trial are expected by the end of June.

Interferon beta is part of the body's first line of defence against viruses, warning it to expect a viral attack.

The coronavirus seems to suppress its production as part of its strategy to evade our immune systems.

The drug is a special formulation of interferon beta delivered directly to the airways when the virus is there, with the hope that a direct dose of the protein will trigger a stronger anti-viral response even in patients whose immune systems are already weak.